PMA · Approved
ApprovedLIAISON XL MUREX HCV Ab, LIAISON XL MUREX Control HCV Ab
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
DiaSorin, Inc. · MZO Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Approved on Aug 10, 2021 through premarket approval, which rests on the device’s own clinical evidence after a 75-day review.
- Decided
- Aug 10, 2021
- Review
- 75 days
- Class
- Class II
- Product code
- MZO
- Recalls
- None
PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.
Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in MZO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new MZO device
- #1 K262156 Anti-HCV Nextscore 12.1 · 1 generation · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
Does it have a predicate?
PMA decisions do not claim a predicate device.
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
How does its category compare?
All MZO devicesMZO Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.
FDA decisions per year · MZO
1in 2023
2026 to Oct 25, outlined.
Median 510(k) review, days · MZO
Too few MZO 510(k)s in any year since 2007 to give a median.
Recalls per year · MZO
1in 2007
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · MZO
208in 2025
MAUDE reports naming product code MZO, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 5 | — | 1 | 20 |
| 2008 | 3 | — | 0 | 21 |
| 2009 | 11 | — | 0 | 86 |
| 2010 | 12 | — | 0 | 51 |
| 2011 | 40 | — | 0 | 76 |
| 2012 | 24 | — | 0 | 136 |
| 2013 | 16 | — | 0 | 119 |
| 2014 | 10 | — | 0 | 57 |
| 2015 | 14 | — | 0 | 41 |
| 2016 | 19 | — | 0 | 115 |
| 2017 | 16 | — | 0 | 116 |
| 2018 | 17 | — | 0 | 153 |
| 2019 | 11 | — | 0 | 138 |
| 2020 | 13 | — | 0 | 47 |
| 2021 | 8 | — | 0 | 26 |
| 2022 | 0 | — | 0 | 56 |
| 2023 | 1 | — | 0 | 55 |
| 2024 | 0 | — | 0 | 56 |
| 2025 | 0 | — | 0 | 208 |
| 2026 | 2 | — | 0 | — |
https://510kreport.com/device/P190011/S004 · printed Nov 5, 2026
Cite this page
510(k) Report. “P190011/S004: LIAISON XL MUREX HCV Ab, LIAISON XL MUREX Control HCV Ab.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/P190011/S004
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Page last updated Nov 3, 2026